What are the causes and consequences of myxomatous degeneration of the mitral leaflet?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Myxomatous Degeneration of Mitral Leaflet: Causes and Consequences

Primary Etiology

Myxomatous degeneration of the mitral leaflet is a primary degenerative condition characterized by intrinsic structural abnormalities of the valve tissue itself, representing the most common cause of primary mitral regurgitation in developed countries 1.

The pathologic process involves:

  • Disruption of collagen fiber microstructure within the leaflet tissue, leading to excessive leaflet extensibility and weakened chordal tissue 2
  • Accumulation of proteoglycans in the valve matrix, causing leaflet thickening and redundancy 1
  • Progressive weakening of chordae tendineae, with reduced stiffness (23.5 ± 3.6 MPa in myxomatous tissue versus 59.1 ± 11.7 MPa in normal tissue) and lower failure stress 3

Clinical Phenotypes

The ACC/ESC guidelines recognize two distinct presentations 4:

  • Barlow disease: Diffuse myxomatous degeneration affecting both leaflets with voluminous, aneurysmal tissue and marked annular dilatation (>40 mm diameter) 5, 2
  • Fibroelastic deficiency (FED): Localized myxomatous changes, typically affecting single segments with less extensive tissue involvement 2

Mechanical Consequences Leading to Mitral Regurgitation

The degenerative process causes mitral regurgitation through two primary mechanisms 3, 6:

  • Chordal rupture: Results from progressive weakening of chordae, creating flail leaflet segments with acute severe regurgitation 3, 6
  • Leaflet prolapse: Excessive leaflet tissue (56.4% ± 7.9% strain versus 42.9% ± 2.7% in normal tissue) billows beyond the mitral annular plane during systole, preventing proper coaptation 3

Important Clinical Distinctions

Myxomatous degeneration must be distinguished from secondary causes of mitral regurgitation 4, 1:

  • In myxomatous disease, the valve apparatus itself is pathologic (primary MR), whereas secondary MR involves structurally normal leaflets with dysfunction from ventricular or atrial pathology 4, 1
  • When mitral regurgitation jets are directed centrally or anteriorly (rather than posteriorly), or when multiple jets are present, suspect myxomatous degeneration as the underlying cause 4

Age-Related Patterns

Myxomatous degeneration shows distinct age-dependent presentations 4:

  • In adults, myxomatous degeneration is the most common cause of chordal rupture, followed by endocarditis, then rheumatic disease 4
  • In the pediatric population (<20 years), chordal rupture predominantly occurs with rheumatic carditis rather than myxomatous disease 4
  • Standard echocardiographic criteria for mitral valve prolapse (≥2 mm billowing visible in multiple views including parasternal long-axis) apply to degenerative myxomatous disease in adults 4

High-Risk Features for Progression

Patients with flail mitral leaflet from myxomatous disease represent a distinct high-risk subset 3:

  • Younger age at presentation (53.7 ± 1.8 years versus 59.3 ± 1.4 years for non-flail prolapse) 3
  • More severe mitral regurgitation at diagnosis 3
  • Paradoxically less likely to be in NYHA class III-IV heart failure at presentation (5% versus 20%), suggesting sudden decompensation rather than gradual progression 3
  • Less likely to have bileaflet involvement (5% versus 38%), indicating focal severe disease 3

Cardiovascular Consequences

Without surgical correction, myxomatous degeneration with severe mitral regurgitation leads to progressive left ventricular dysfunction and increased mortality 1, 3:

  • Chronic volume overload causes left ventricular dilatation and eventual systolic dysfunction 1
  • Elevated left atrial pressure leads to pulmonary hypertension and right ventricular dysfunction 4
  • Survival is significantly impaired without timely surgical intervention 3

Critical Management Principle

Surgery is the only treatment proven to improve symptoms and prevent heart failure in severe mitral regurgitation from myxomatous disease 1:

  • Valve repair reduces mortality by approximately 70% compared to medical management alone 1
  • Early surgical intervention is advocated given the intrinsic tissue abnormalities and risk of sudden chordal rupture 3
  • Emergency surgery is required for acute papillary muscle or chordal rupture presenting with cardiogenic shock or pulmonary edema 1

Common Pitfall

In patients with bicuspid aortic valve regurgitation and aortic root dilatation, isolated aortic valve replacement (without root replacement) carries significantly increased risk of late myxomatous mitral regurgitation (62% versus 0% at 15 years), suggesting a shared connective tissue abnormality 7. Consider this association when planning aortic interventions in BAV patients.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.